| Autor: |
Rizzo, F, Mandurino Mirizzi, A, Tondo, A, Fischetti, D, Quarta, L, Corlianò, L, Mussardo, M, Cafaro, A, Germinal, F, Picciolo, A, Colonna, G |
| Zdroj: |
European Heart Journal Supplements: Journal of the European Society of Cardiology; May 2023, Vol. 25 Issue: 1, Number 1 Supplement 4 pD80-D80, 1p |
| Abstrakt: |
Intro Cangrelor, an intravenous P2Y12 receptor inhibitor (P2Y12i), characterized by rapid onset and offset of antiplatelet action, is approved by guidelines for patients P2Y12i naïve undergoing percutaneous coronary intervention (PCI). Cangrelor infusion duration and time of transition to oral P2Y12i are still debated, although there is a general indication to an infusion of at least 2 hours. The aim of our study is to evaluate the efficacy and the safety of an early transition to oral P2Y12i strategy. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
